SEARCH

SEARCH BY CITATION

References

  • Albers D. S. and Beal M. F. (2000) Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural Transm. Suppl. 59, 133154.
  • Allinson T. M., Parkin E. T., Turner A. J. and Hooper N. M. (2003) ADAMs family members as amyloid precursor protein alpha-secretases. J. Neurosci. Res. 74, 342352.
  • Avdulov N. A., Chochina S. V., Igbavboa U., Warden C. S., Vassiliev A. V. and Wood W. G. (1997) Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 69, 17461752.
  • Barberger-Gateau P., Letenneur L., Deschamps V., Peres K., Dartigues J. F. and Renaud S. (2002) Fish, meat, and risk of dementia: cohort study. BMJ 325, 932933.
  • Bassett C. N. and Montine T. J. (2003) Lipoproteins and lipid peroxidation in Alzheimer’s disease. J. Nutr. Health Aging 7, 2429.
  • Black R. A., Rauch C. T., Kozlosky C. J., Peschon J. J., Slack J. L., Wolfson M. F., Castner B. J., Stocking K. L., Reddy P., Srinivasan S., et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729733.
  • Blacker M., Noe M. C., Carty T. J., Goodyer C. G. and LeBlanc A. C. (2002) Effect of tumor necrosis factor-alpha converting enzyme (TACE) and metalloprotease inhibitor on amyloid precursor protein metabolism in human neurons. J. Neurochem. 83, 13491357.
  • Blennow K., Davidsson P., Wallin A., Fredman P., Gottfries C. G., Karlsson I., Mansson J. E. and Svennerholm L. (1991) Gangliosides in cerebrospinal fluid in ‘probable Alzheimer’s disease’. Arch. Neurol. 48, 10321035.
  • Brookmeyer R., Gray S. and Kawas C. (1998) Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88, 13371342.
  • Brown A. J., Sun L., Feramisco J. D., Brown M. S. and Goldstein J. L. (2002) Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. Mol. Cell 10, 237245.
  • Brown M. S., Ye J., Rawson R. B. and Goldstein J. L. (2000) Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100, 391398.
  • Buxbaum J. D., Koo E. H. and Greengard P. (1993) Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc. Natl Acad. Sci. USA 90, 91959198.
  • Buxbaum J. D., Liu K. N., Luo Y., Slack J. L., Stocking K. L., Peschon J. J., Johnson R. S., Castner B. J., Cerretti D. P. and Black R. A. (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273, 2776527767.
  • Cai H., Wang Y., McCarthy D., Wen H., Borchelt D. R., Price D. L. and Wong P. C. (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4, 233234.
  • Cedazo-Minguez A., Wiehager B., Winblad B., Huttinger M. and Cowburn R. F. (2001) Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts. Neurochem. Int. 38, 615625.
  • Cheng H., Xu J., McKeel D. W. Jr and Han X. (2003) Specificity and potential mechanism of sulfatide deficiency in Alzheimer’s disease: an electrospray ionization mass spectrometric study. Cell. Mol. Biol. (Noisy-le-grand) 49, 809818.
  • Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L. and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921923.
  • Cutler R. G., Kelly J., Storie K., Pedersen W. A., Tammara A., Hatanpaa K., Troncoso J. C. and Mattson M. P. (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc. Natl Acad. Sci. USA 101, 20702075.
  • Davis J. B. (1996) Oxidative mechanisms in beta-amyloid cytotoxicity. Neurodegeneration 5, 441444.
  • De Strooper B. (2003) Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 38, 912.
  • Di Marzo V. (1995) Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. Prostaglandins Leukot. Essent. Fatty Acids 53, 239254.
  • Dietschy J. M. and Turley S. D. (2004) Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45, 13751397.
  • Doan A., Thinakaran G., Borchelt D. R., Slunt H. H., Ratovitsky T., Podlisny M., Selkoe D. J., Seeger M., Gandy S. E., Price D. L. and Sisodia S. S. (1996) Protein topology of presenilin 1. Neuron 17, 10231030.
  • Duering M., Grimm M. O., Grimm H. S., Schroder J. and Hartmann T. (2005) Mean age of onset in familial Alzheimer’s disease is determined by amyloid beta 42. Neurobiol. Aging 26, 785788.
  • Ehehalt R., Keller P., Haass C., Thiele C. and Simons K. (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113123.
  • Farooqui A. A. and Horrocks L. A. (2001) Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 7, 232245.
  • Farooqui A. A., Ong W. Y. and Horrocks L. A. (2003) Plasmalogens, docosahexaenoic acid and neurological disorders. Adv. Exp. Med. Biol. 544, 335354.
  • Farooqui A. A., Yang H. C. and Horrocks L. A. (1995) Plasmalogens, phospholipases A2 and signal transduction. Brain Res. Brain Res. Rev. 21, 152161.
  • Farzan M., Schnitzler C. E., Vasilieva N., Leung D. and Choe H. (2000) BACE2, a beta-secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc. Natl Acad. Sci. USA 97, 97129717.
  • Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., Von Bergmann K., et al. (2001) Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 58565861.
  • Ferri C. P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 21122117.
  • Fluhrer R., Multhaup G., Schlicksupp A., Okochi M., Takeda M., Lammich S., Willem M., Westmeyer G., Bode W., Walter J. and Haass C. (2003) Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. J. Biol. Chem. 278, 55315538.
  • Fraering P. C., Ye W., Strub J. M., Dolios G., LaVoie M. J., Ostaszewski B. L., Van Dorsselaer A., Wang R., Selkoe D. J. and Wolfe M. S. (2004) Purification and characterization of the human gamma-secretase complex. Biochemistry 43, 97749789.
  • Francis R., McGrath G., Zhang J., Ruddy D. A., Sym M., Apfeld J., Nicoll M., Maxwell M., Hai B., Ellis M. C., et al. (2002) aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell 3, 8597.
  • Freund-Levi Y., Eriksdotter-Jonhagen M., Cederholm T., Basun H., Faxen-Irving G., Garlind A., Vedin I., Vessby B., Wahlund L. O. and Palmblad J. (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 63, 14021408.
  • Friesen J. A. and Rodwell V. W. (2004) The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol. 5, 248.
  • Furukawa K., Sopher B. L., Rydel R. E., Begley J. G., Pham D. G., Martin G. M., Fox M. and Mattson M. P. (1996) Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem. 67, 18821896.
  • Ginsberg L., Rafique S., Xuereb J. H., Rapoport S. I. and Gershfeld N. L. (1995) Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res. 698, 223226.
  • Ginsberg L., Xuereb J. H. and Gershfeld N. L. (1998) Membrane instability, plasmalogen content, and Alzheimer’s disease. J. Neurochem. 70, 25332538.
  • Goutte C., Tsunozaki M., Hale V. A. and Priess J. R. (2002) APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc. Natl Acad. Sci. USA 99, 775779.
  • Grimm M. O., Grimm H. S., Patzold A. J., Zinser E. G., Halonen R., Duering M., Tschape J. A., De Strooper B., Muller U., Shen J. and Hartmann T. (2005) Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7, 11181123.
  • Grimm M. O., Tomic I. and Hartmann T. (2002) Potential external source of A beta in biological samples. Nat. Cell Biol. 4, E164E165.
  • Grimm M. O., Tschape J. A., Grimm H. S., Zinser E. G. and Hartmann T. (2006) Altered membrane fluidity and lipid raft composition in presenilin-deficient cells. Acta Neurol. Scand Suppl. 185, 2732.
  • Grziwa B., Grimm M. O., Masters C. L., Beyreuther K., Hartmann T. and Lichtenthaler S. F. (2003) The transmembrane domain of the amyloid precursor protein in microsomal membranes is on both sides shorter than predicted. J. Biol. Chem. 278, 68036808.
  • Guan Z., Wang Y., Cairns N. J., Lantos P. L., Dallner G. and Sindelar P. J. (1999) Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J. Neuropathol. Exp. Neurol. 58, 740747.
  • Han X (2005) Lipid alterations in the earliest clinically recognizable stage of Alzheimer’s disease: implication of the role of lipids in the pathogenesis of Alzheimer’s disease. Curr. Alzheimer Res. 2, 6577.
  • Han X., D M. H., McKeel D. W. Jr, Kelley J. and Morris J. C. (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: potential role in disease pathogenesis. J. Neurochem. 82, 809818.
  • Han X., Holtzman D. M., McKeel D. W. Jr. (2001) Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77, 11681180.
  • Hardy J. A. and Higgins G. A. (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184185.
  • Hartmann D., De Strooper B., Serneels L., Craessaerts K., Herreman A., Annaert W., Umans L., Lubke T., Lena Illert A., Von Figura K. and Saftig P. (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum. Mol. Genet. 11, 26152624.
  • Hartmann T., Bieger S. C., Bruhl B., Tienari P. J., Ida N., Allsop D., Roberts G. W., Masters C. L., Dotti C. G., Unsicker K. and Beyreuther K. (1997) Distinct sites of intracellular production for Alzheimer’s disease A beta40/42 amyloid peptides. Nat. Med. 3, 10161020.
  • Hashimoto M., Hossain S., Shimada T., Sugioka K., Yamasaki H., Fujii Y., Ishibashi Y., Oka J. and Shido O. (2002) Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer’s disease model rats. J. Neurochem. 81, 10841091.
  • Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E and Blennow K. (2004) Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch. Neurol. 61, 333337.
  • Huse J. T., Pijak D. S., Leslie G. J., Lee V. M. and Doms R. W. (2000) Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer’s disease beta-secretase. J. Biol. Chem. 275, 3372933737.
  • Hwang E. M., Kim S. K., Sohn J. H., Lee J. Y., Kim Y., Kim Y. S. and Mook-Jung I. (2006) Furin is an endogenous regulator of alpha-secretase associated APP processing. Biochem. Biophys. Res. Commun. 349, 654659.
  • Ishizuka I. (1997) Chemistry and functional distribution of sulfoglycolipids. Prog. Lipid Res. 36, 245319.
  • Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N. and Ihara Y. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13, 4553.
  • Jick H., Zornberg G. L., Jick S. S., Seshadri S. and Drachman D. A. (2000) Statins and the risk of dementia. Lancet 356, 16271631.
  • Kaether C., Haass C. and Steiner H. (2006) Assembly, trafficking and function of gamma-secretase. Neurodegener. Dis. 3, 275283.
  • Kalmijn S., Launer L. J., Ott A., Witteman J. C., Hofman A. and Breteler M. M. (1997) Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann. Neurol. 42, 776782.
  • Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K. and Muller-Hill B. (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733736.
  • Kitazume S., Saido T. C. and Hashimoto Y. (2004) Alzheimer’s beta-secretase cleaves a glycosyltransferase as a physiological substrate. Glycoconj. J. 20, 5962.
  • Kitazume S., Tachida Y., Oka R., Nakagawa K., Takashima S., Lee Y. C. and Hashimoto Y. (2006) Screening a series of sialyltransferases for possible BACE1 substrates. Glycoconj. J. 23, 437441.
  • Kivipelto M., Helkala E. L., Laakso M. P., Hanninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J. and Nissinen A. (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 322, 14471451.
  • Koike H., Tomioka S., Sorimachi H., Saido T. C., Maruyama K., Okuyama A., Fujisawa-Sehara A., Ohno S., Suzuki K. and Ishiura S. (1999) Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem. J. 2(343 Pt), 371375.
  • Koo E. H. and Squazzo S. L. (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269, 1738617389.
  • Kracun I., Kalanj S., Cosovic C. and Talan-Hranilovic J. (1990) Brain gangliosides in Alzheimer’s disease. J. Hirnforsch 31, 789793.
  • Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C. and Fahrenholz F. (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl Acad. Sci. USA 96, 39223927.
  • Laudon H., Hansson E. M., Melen K., Bergman A., Farmery M. R., Winblad B., Lendahl U., Von Heijne G. and Naslund J. (2005) A nine-transmembrane domain topology for presenilin 1. J. Biol. Chem. 280, 3535235360.
  • LeBlanc A. C., Koutroumanis M. and Goodyer C. G. (1998) Protein kinase C activation increases release of secreted amyloid precursor protein without decreasing Abeta production in human primary neuron cultures. J. Neurosci. 18, 29072913.
  • Lee S. F., Shah S., Li H., Yu C., Han W. and Yu G. (2002) Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch. J. Biol. Chem. 277, 4501345019.
  • Lichtenthaler S. F., Dominguez D. I., Westmeyer G. G., Reiss K., Haass C., Saftig P., De Strooper B. and Seed B. (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 278, 4871348719.
  • Lim G. P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., Salem N. Jr, Frautschy S. A. and Cole G. M. (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25, 30323040.
  • Luo Y., Bolon B., Kahn S., Bennett B. D., Babu-Khan S., Denis P., Fan W., Kha H., Zhang J., Gong Y., et al. (2001) Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4, 231232.
  • Markesbery W. R. and Carney J. M. (1999) Oxidative alterations in Alzheimer’s disease. Brain Pathol. 9, 133146.
  • Masters C. L. and Beyreuther K. T. (1989) The pathology of the amyloid A4 precursor of Alzheimer’s disease. Ann. Med. 21, 8990.
  • Masters C. L., Cappai R., Barnham K. J. and Villemagne V. L. (2006) Molecular mechanisms for Alzheimer’s disease: implications for neuroimaging and therapeutics. J. Neurochem. 97, 17001725.
  • Matsuoka Y., Saito M., LaFrancois J., Gaynor K., Olm V., Wang L., Casey E., Lu Y., Shiratori C., Lemere C. and Duff K. (2003) Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 23, 2933.
  • Mattson M. P., Guo Z. H. and Geiger J. D. (1999) Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. J. Neurochem. 73, 532537.
  • Meziane H., Dodart J. C., Mathis C., Little S., Clemens J., Paul S. M. and Ungerer A. (1998) Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc. Natl Acad. Sci. USA 95, 1268312688.
  • Michal G. (1999). Biochemical Pathways. Spektrum Akademischer Verlag, Heidelberg, Berlin.
  • Mills J. and Reiner P. B. (1999) Regulation of amyloid precursor protein cleavage. J. Neurochem. 72, 443460.
  • Montine T. J. and Morrow J. D. (2005) Fatty acid oxidation in the pathogenesis of Alzheimer’s disease. Am. J. Pathol. 166, 12831289.
  • Morris M. C., Evans D. A., Bienias J. L., Tangney C. C., Bennett D. A., Wilson R. S., Aggarwal N. and Schneider J. (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 60, 940946.
  • Moss M. L., Jin S. L., Milla M. E., Bickett D. M., Burkhart W., Carter H. L., Chen W. J., Clay W. C., Didsbury J. R., Hassler D., et al. (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385, 733736.
  • Mulder C., Wahlund L. O., Teerlink T., Blomberg M., Veerhuis R., Van Kamp G. J., Scheltens P. and Scheffer P. G. (2003) Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer’s disease. J. Neural Transm. 110, 949955.
  • Muniz M., Morsomme P. and Riezman H. (2001) Protein sorting upon exit from the endoplasmic reticulum. Cell 104, 313320.
  • Oh Y. S. and Turner R. J. (2005a) Evidence that the COOH terminus of human presenilin 1 is located in extracytoplasmic space. Am. J. Physiol. Cell Physiol. 289, C576C581.
  • Oh Y. S. and Turner R. J. (2005b) Topology of the C-terminal fragment of human presenilin 1. Biochemistry 44, 1182111828.
  • Oksman M., Iivonen H., Hogyes E., Amtul Z., Penke B., Leenders I., Broersen L., Lutjohann D., Hartmann T. and Tanila H. (2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 23, 563572.
  • Papassotiropoulos A., Lutjohann D., Bagli M., Locatelli S., Jessen F., Rao M. L., Maier W., Bjorkhem I., Von Bergmann K. and Heun R. (2000) Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer’s disease. Neuroreport 11, 19591962.
  • Pettegrew J. W., Klunk W. E., Kanal E., Panchalingam K. and McClure R. J. (1995) Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol. Aging 16, 973975.
  • Pfrieger F. W. (2003) Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol. Life Sci. 60, 11581171.
  • Poirier J., Baccichet A., Dea D. and Gauthier S. (1993) Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 55, 8190.
  • Prasad M. R., Lovell M. A., Yatin M., Dhillon H. and Markesbery W. R. (1998) Regional membrane phospholipid alterations in Alzheimer’s disease. Neurochem. Res. 23, 8188.
  • Puglielli L., Konopka G., Pack-Chung E., Ingano L. A., Berezovska O., Hyman B. T., Chang T. Y., Tanzi R. E. and Kovacs D. M. (2001) Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3, 905912.
  • Ratovitski T., Slunt H. H., Thinakaran G., Price D. L., Sisodia S. S. and Borchelt D. R. (1997) Endoproteolytic processing and stabilization of wild-type and mutant presenilin. J. Biol. Chem. 272, 2453624541.
  • Refolo L. M., Pappolla M. A., LaFrancois J., Malester B., Schmidt S. D., Thomas-Bryant T., Tint G. S., Wang R., Mercken M., Petanceska S. S. and Duff K. E. (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol. Dis. 8, 890899.
  • Roberds S. L., Anderson J., Basi G., Bienkowski M. J., Branstetter D. G., Chen K. S., Freedman S. B., Frigon N. L., Games D., Hu K., et al. (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum. Mol. Genet. 10, 13171324.
  • Rockwood K., Kirkland S., Hogan D. B., MacKnight C., Merry H., Verreault R., Wolfson C. and McDowell I. (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59, 223227.
  • Selkoe D. and Kopan R. (2003) Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci. 26, 565597.
  • Selkoe D. J. (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 81, 741766.
  • Selley M. L., Close D. R. and Stern S. E. (2002) The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer’s disease. Neurobiol. Aging 23, 383388.
  • Shie F. S., Jin L. W., Cook D. G., Leverenz J. B. and LeBoeuf R. C. (2002) Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13, 455459.
  • Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. G. and Simons K. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 64606464.
  • Simons M., Schwarzler F., Lutjohann D., Von Bergmann K., Beyreuther K., Dichgans J., Wormstall H., Hartmann T. and Schulz J. B. (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52, 346350.
  • Sisodia S. S. and St George-Hyslop P. H. (2002) Gamma-secretase, notch, abeta and Alzheimer’s disease: where do the presenilins fit in? Nat. Rev. Neurosci. 3, 281290.
  • Skovronsky D. M., Fath S., Lee V. M. and Milla M. E. (2001) Neuronal localization of the TNFalpha converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. J. Neurobiol. 49, 4046.
  • Smith E. R., Merrill A. H., Obeid L. M. and Hannun Y. A. (2000) Effects of sphingosine and other sphingolipids on protein kinase C. Methods Enzymol. 312, 361373.
  • Soderberg M., Edlund C., Kristensson K. and Dallner G. (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease. Lipids 26, 421425.
  • Sparks D. L., Sabbagh M. N., Connor D. J., Lopez J., Launer L. J., Browne P., Wasser D., Johnson-Traver S., Lochhead J. and Ziolwolski C. (2005) Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 62, 753757.
  • Steinberg D. (2006) Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J. Lipid Res. 47, 13391351.
  • Steiner H., Winkler E., Edbauer D., Prokop S., Basset G., Yamasaki A., Kostka M. and Haass C. (2002) PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin. J. Biol. Chem. 277, 3906239065.
  • Svennerholm L., Bostrom K., Jungbjer B. and Olsson L. (1994) Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. J. Neurochem. 63, 18021811.
  • Tamboli I. Y., Prager K., Barth E., Heneka M., Sandhoff K. and Walter J. (2005) Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J. Biol. Chem. 280, 2811028117.
  • Thevissen K., Francois I. E., Winderickx J., Pannecouque C. and Cammue B. P. (2006) Ceramide involvement in apoptosis and apoptotic diseases. Mini. Rev. Med. Chem. 6, 699709.
  • Thinakaran G., Borchelt D. R., Lee M. K., Slunt H. H., Spitzer L., Kim G., Ratovitsky T., Davenport F., Nordstedt C., Seeger M., et al. (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17, 181190.
  • Tully A. M., Roche H. M., Doyle R., Fallon C., Bruce I., Lawlor B., Coakley D. and Gibney M. J. (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer’s disease: a case-control study. Br. J. Nutr. 89, 483489.
  • Vassar R. (2001) The beta-secretase, BACE: a prime drug target for Alzheimer’s disease. J. Mol. Neurosci. 17, 157170.
  • Vassar R., Bennett B. D., Babu-Khan S., Kahn S., Mendiaz E. A., Denis P., Teplow D. B., Ross S., Amarante P., Loeloff R., et al. (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735741.
  • Venkataraman K. and Futerman A. H. (2000) Ceramide as a second messenger: sticky solutions to sticky problems. Trends Cell Biol. 10, 408412.
  • Von Strauss E., Viitanen M., De Ronchi D., Winblad B. and Fratiglioni L. (1999) Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch. Neurol. 56, 587592.
  • Vos J. P., Lopes-Cardozo M. and Gadella B. M. (1994) Metabolic and functional aspects of sulfogalactolipids. Biochim. Biophys. Acta 1211, 125149.
  • Wahrle S., Das P., Nyborg A. C., McLendon C., Shoji M., Kawarabayashi T., Younkin L. H., Younkin S. G. and Golde T. E. (2002) Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9, 1123.
  • Weisser M., Vieth M., Stolte M., Riederer P., Pfeuffer R., Leblhuber F. and Spiteller G. (1997) Dramatic increase of alpha-hydroxyaldehydes derived from plasmalogens in the aged human brain. Chem. Phys. Lipids 90, 135142.
  • Wells K., Farooqui A. A., Liss L. and Horrocks L. A. (1995) Neural membrane phospholipids in Alzheimer disease. Neurochem. Res. 20, 13291333.
  • Weskamp G., Cai H., Brodie T. A., Higashyama S., Manova K., Ludwig T. and Blobel C. P. (2002) Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol. Cell Biol. 22, 15371544.
  • Weskamp G., Kratzschmar J., Reid M. S. and Blobel C. P. (1996) MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. J. Cell Biol. 132, 717726.
  • Willem M., Garratt A. N., Novak B., Citron M., Kaufmann S., Rittger A., DeStrooper B., Saftig P., Birchmeier C. and Haass C. (2006) Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314, 664666.
  • Wolozin B., Kellman W., Ruosseau P., Celesia G. G. and Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 14391443.
  • Wood W. G., Schroeder F., Igbavboa U., Avdulov N. A. and Chochina S. V. (2002) Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol. Aging 23, 685694.
  • Younkin S. G. (1991) Processing of the Alzheimer’s disease beta A4 amyloid protein precursor (APP). Brain Pathol. 1, 253262.
  • Zha Q., Ruan Y., Hartmann T., Beyreuther K. and Zhang D. (2004) GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol. Psychiatry 9, 946952.